Literature DB >> 28683323

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

Nora Pencheva1, Mark C de Gooijer2, Daniel J Vis1, Lodewyk F A Wessels1, Tom Würdinger3, Olaf van Tellingen4, René Bernards5.   

Abstract

Diffuse and uncontrollable brain invasion is a hallmark of glioblastoma (GBM), but its mechanism is understood poorly. We developed a 3D ex vivo organotypic model to study GBM invasion. We demonstrate that invading GBM cells upregulate a network of extracellular matrix (ECM) components, including multiple collagens, whose expression correlates strongly with grade and clinical outcome. We identify interferon regulatory factor 3 (IRF3) as a transcriptional repressor of ECM factors and show that IRF3 acts as a suppressor of GBM invasion. Therapeutic activation of IRF3 by inhibiting casein kinase 2 (CK2)-a negative regulator of IRF3-downregulated the expression of ECM factors and suppressed GBM invasion in ex vivo and in vivo models across a panel of patient-derived GBM cell lines representative of the main molecular GBM subtypes. Our data provide mechanistic insight into the invasive capacity of GBM tumors and identify a potential therapy to inhibit GBM invasion.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  casein kinase 2; collagen; extracellular matrix; glioblastoma; interferon regulatory factor 3; invasion

Mesh:

Substances:

Year:  2017        PMID: 28683323     DOI: 10.1016/j.celrep.2017.06.036

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  27 in total

1.  Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion.

Authors:  Siobhan S Pattwell; Eric C Holland
Journal:  Trends Mol Med       Date:  2017-07-31       Impact factor: 11.951

2.  Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles.

Authors:  Gabriela D A Guardia; Bruna R Correa; Patricia Rosa Araujo; Mei Qiao; Suzanne Burns; Luiz O F Penalva; Pedro A F Galante
Journal:  NPJ Genom Med       Date:  2020-01-16       Impact factor: 8.617

3.  Dissecting Glioma Invasiveness in a 3D-Organotypic Model.

Authors:  Paolo Codega; Ingo K Mellinghoff
Journal:  Trends Mol Med       Date:  2017-08-03       Impact factor: 11.951

Review 4.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

5.  Interferon signaling during Hepatitis B Virus (HBV) infection and HBV-associated hepatocellular carcinoma.

Authors:  Saravana Kumar Kailasam Mani; Ourania Andrisani
Journal:  Cytokine       Date:  2018-08-17       Impact factor: 3.861

6.  NOX2-Induced High Glycolytic Activity Contributes to the Gain of COL5A1-Mediated Mesenchymal Phenotype in GBM.

Authors:  Youngjoon Park; Minwoo Park; Junhyung Kim; Juwon Ahn; Jeongmin Sim; Ji-In Bang; Jinhyung Heo; Hyejeong Choi; Kyunggi Cho; Mihye Lee; Jong-Seok Moon; Jaejoon Lim
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

7.  Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.

Authors:  Yuting Lu; Yongzhao Shao
Journal:  Cancer Drug Resist       Date:  2022-06-02

Review 8.  The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.

Authors:  Rui Sun; Albert H Kim
Journal:  Cancer Metastasis Rev       Date:  2022-08-03       Impact factor: 9.237

9.  Development of a potent and selective chemical probe for the pleiotropic kinase CK2.

Authors:  Carrow I Wells; David H Drewry; Julie E Pickett; Amelie Tjaden; Andreas Krämer; Susanne Müller; Laszlo Gyenis; Daniel Menyhart; David W Litchfield; Stefan Knapp; Alison D Axtman
Journal:  Cell Chem Biol       Date:  2021-01-22       Impact factor: 8.116

Review 10.  In Vitro Glioblastoma Models: A Journey into the Third Dimension.

Authors:  Mayra Paolillo; Sergio Comincini; Sergio Schinelli
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.